Katherine Kedzierska Selected Research

deoxythymidine 3',5'-bis-(p-nitrophenyl phosphate)

2/2012	Consequences of suboptimal priming are apparent for low-avidity T-cell responses.
9/2010	Fixing an irrelevant TCR alpha chain reveals the importance of TCR beta diversity for optimal TCR alpha beta pairing and function of virus-specific CD8+ T cells.
3/2010	Diversity and clonotypic composition of influenza-specific CD8+ TCR repertoires remain unaltered in the absence of Aire.
12/2008	Complete modification of TCR specificity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy.
8/2008	Terminal deoxynucleotidyltransferase is required for the establishment of private virus-specific CD8+ TCR repertoires and facilitates optimal CTL responses.
6/2008	Homogenization of TCR repertoires within secondary CD62Lhigh and CD62Llow virus-specific CD8+ T cell populations.
6/2006	Early establishment of diverse T cell receptor profiles for influenza-specific CD8(+)CD62L(hi) memory T cells.
1/2006	A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katherine Kedzierska Research Topics

Disease

75	Infections 06/2022 - 03/2002
61	Human Influenza (Influenza) 01/2022 - 06/2004
16	COVID-19 01/2022 - 01/2020
12	Virus Diseases (Viral Diseases) 06/2022 - 08/2007
6	Inflammation (Inflammations) 01/2022 - 01/2015
6	Neoplasms (Cancer) 02/2021 - 05/2011
4	Malaria 01/2021 - 01/2020
3	Communicable Diseases (Infectious Diseases) 01/2021 - 12/2014
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 12/2014
2	Rheumatoid Arthritis 01/2022 - 11/2017
2	Bacterial Infections (Bacterial Infection) 01/2022 - 01/2020
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 01/2017
2	Cytokine Release Syndrome 05/2014 - 01/2014
1	RNA Virus Infections 06/2022
1	Multiple Sclerosis 01/2022
1	Tularemia 01/2022
1	Convalescence 11/2021
1	Lymphoma (Lymphomas) 09/2021
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2021
1	Reinfection 01/2020
1	Neglected Diseases 01/2020
1	Parasitic Diseases (Parasitic Disease) 01/2020

Drug/Important Bio-Agent (IBA)

37	VaccinesIBA 01/2022 - 01/2009
27	EpitopesIBA 01/2022 - 06/2004
21	AntigensIBA 01/2022 - 06/2004
20	CytokinesIBA 06/2022 - 11/2002
17	Peptides (Polypeptides)IBA 01/2022 - 04/2005
10	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2002
10	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 06/2006
8	ChemokinesIBA 06/2022 - 11/2002
8	AntibodiesIBA 01/2022 - 12/2014
8	HLA-A Antigens (HLA-A)IBA 01/2022 - 04/2016
8	deoxythymidine 3',5'-bis-(p-nitrophenyl phosphate)IBA 02/2012 - 01/2006
7	Antiviral Agents (Antivirals)IBA 06/2022 - 01/2014
7	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022 - 01/2014
5	Hemagglutinins (Hemagglutinin)IBA 01/2022 - 07/2017
5	Granzymes (Granzyme)IBA 01/2020 - 09/2008
4	HLA-A*24:02 antigenIBA 01/2022 - 04/2016
4	NucleoproteinsIBA 05/2011 - 04/2005
3	Interferon Type IIBA 06/2022 - 01/2014
3	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2022 - 05/2011
3	HLA Antigens (Human Leukocyte Antigens)IBA 11/2021 - 01/2020
3	Pattern Recognition ReceptorsIBA 01/2021 - 10/2019
3	InterferonsIBA 01/2021 - 01/2014
3	PerforinIBA 01/2020 - 09/2008
3	Neutralizing AntibodiesIBA 02/2016 - 01/2015
3	LipopeptidesIBA 05/2012 - 03/2006
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 08/2021
2	Riboflavin (Vitamin B2)FDA LinkGeneric 01/2022 - 12/2019
2	Glycoproteins (Glycoprotein)IBA 10/2021 - 01/2006
2	Immunoglobulin G (IgG)IBA 08/2021 - 01/2021
2	LigandsIBA 02/2021 - 01/2014
2	Interleukin-18 (Interleukin 18)IBA 01/2021 - 01/2016
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021 - 02/2003
2	Viral RNAIBA 01/2021 - 01/2014
2	HLA-DR Antigens (HLA-DR)IBA 01/2021 - 01/2020
2	Interleukin-10 (Interleukin 10)IBA 01/2021 - 11/2008
2	Neuraminidase (Sialidase)IBA 11/2020 - 01/2015
2	Oseltamivir (Tamiflu)FDA Link 11/2020 - 01/2015
2	HLA-B Antigens (HLA-B)IBA 01/2020 - 04/2016
2	GlycolipidsIBA 01/2020 - 11/2017
2	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2020 - 05/2011
2	Interleukin-2 (IL2)IBA 01/2020 - 08/2007
2	Immunologic Factors (Immunomodulators)IBA 01/2015 - 02/2007
2	AcidsIBA 11/2006 - 04/2005
2	Amino Acids FDA Link 01/2006 - 04/2005
1	Interleukin-12 (IL 12)IBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022
1	Interleukin-23 (Interleukin 23)IBA 01/2022
1	Subunit VaccinesIBA 10/2021
1	Immunoglobulin M (IgM)IBA 08/2021
1	Immunoglobulin A (IgA)IBA 08/2021
1	remdesivirIBA 08/2021
1	Leptin ReceptorsIBA 01/2021
1	Polysaccharides (Glycans)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Detergents (Detergent)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	LeptinIBA 01/2021
1	Ether (Diethyl Ether)IBA 01/2021
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	Zanamivir (Relenza)FDA Link 11/2020
1	aminoxanideIBA 11/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2020
1	Dinoprostone (PGE2)FDA Link 10/2020
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 10/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2020
1	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	RezafunginIBA 01/2020

Therapy/Procedure

8	Immunotherapy 10/2021 - 01/2016
8	Therapeutics 09/2021 - 02/2003
3	Drug Therapy (Chemotherapy) 01/2022 - 03/2004
2	Highly Active Antiretroviral Therapy (HAART) 05/2006 - 01/2005
1	Local Anesthesia 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2021